Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie’s Disease— A Placebo-Controlled Pilot Study
The DOI matches its Crossref record.
Abstract
Introduction: Transdermal and intralesional verapamil has been reported to be useful in the treatment of Peyronie’s Disease. This study evaluates a topically applied calcium channel blocker (verapamil hydrochloride 15% gel), a topically applied calmodulin blocker (trifluoperazine), and a topically applied weak calcium channel blocker (magnesium sulfate), each incorporated in a transdermal vehicle. Aim: This pilot study was conducted to assess the efficacy of a 15% verapamil gel applied topically to the penile shaft twice daily for the treatment of Peyronie’s Disease. Main Outcome Measure: To assess improvement in curvature, plaque size, resolution of painful erections, and improvement in erection quality. Methods: Two simultaneous, three armed, double blinded, placebo-controlled studies were conducted. After randomization into one of four groups, patients were treated for 3 months. At the end of 3 months’ treatment using blinded drug, each patient was treated with open label topical verapamil for 6 months. The studies were completed after each patient had been treated and evaluated for 9 months after randomization. Results: Fifty-seven patients were randomized. In total, 94.4% of patients treated for 9 months with topical verapamil experienced improvement in curvature with an average percent curvature change of 61.1% compared with 43.6% curvature improvement at 3 months. At 9 months the average percent plaque change was 84.7% compared with 55% at 3 months. Pain resolution at 9 months was 100% compared with 87.5% at 3 months. Patient perception of erection quality also increased at 9 months to 81.8% compared with 72.7% at 3 months. Conclusion: Topical verapamil gel proved effective in eliminating pain on erection, decreasing the size of plaque, decreasing curvature, and improving erection quality in patients with Peyronie’s Disease. Treatment results improved significantly after 9 months’ treatment as compared with 3 months’ treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309
Psychological Impact of Peyronie's Disease: A Review
Nelson, C. J., & Mulhall, J. P. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02999.x · Cited by 187
Peyronie’s disease: Contemporary evaluation and management
Ziegelmann, M. J., Bajic, P., & Levine, L. A. (2020) · International Journal of Urology · doi:10.1111/iju.14230 · Cited by 86
Bella, A. J., Lee, J. C., Grober, E. D., Carrier, S., Benard, F., & Brock, G. B. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5255 · Cited by 68
Nonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Metadata
- Authors
- Fitch, Easterling, W. J., Talbert, R. L., Bordovsky, M. J., & Mosier, M.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 4
- Issue
- 2
- Pages
- 477-484
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W2146483003
- Cited by
- 84
- References
- 0
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie’s Disease— A Placebo-Controlled Pilot Study. https://app.cochat.ai/papers/10.1111/j.1743-6109.2006.00417.x
- The paper
- Fitch, Easterling, W. J., Talbert, R. L., Bordovsky, M. J., & Mosier, M. (2007). Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie’s Disease— A Placebo-Controlled Pilot Study. The Journal of Sexual Medicine. https://doi.org/10.1111/j.1743-6109.2006.00417.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.